explore -WSS

explore

author：entertainment 2025-09-28 02:31:01 - browse：8

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Stroke deaths set to near 10 million globally by 2050

WSS

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

What to expect at HLTH 2023, the health care industry conference

Twitch streamer Kai Cenat speaks out for 1st time since causing mayhem with Union Square giveaway

What to expect at HLTH 2023, the health care industry conference

3 questions for the future of Biden's cancer moonshot

Emergent cuts jobs, executive role in business shake

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

New air purifier tech could be key to improving indoor air quality

Anavex keeps shifting the goalposts in its clinical trials

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Sana to lay off nearly a third of staff, de

Moonlake's readout produced a cash windfall. Risks remain

Amylyx's ALS drug launch starts strong. It could be trouble for FDA

Supreme Court strikes down use of affirmative action

Why Charlie Gard's case is so disturbing to Americans

Walensky prepares to leave CDC — and Congress — behind

Emergent cuts jobs, executive role in business shake

Wikipedia

Police still searching for prisoner who escaped from NYC hospital

FDA panel issues narrow recommendation for Covid vaccine booster doses

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Colorectal cancer study finds potential in overlooked immune cell

Was Amgen transparent enough on FDA's concern on cancer drug?

The best solution to the drug shortages problem

focus

entertainment

explore

Wikipedia